Company intelligence / Profile preview

PeptiSystems

Ownership: Private
Development stage: Commercial

Overview

Since launching its products in 2021, PeptiSystems has seen strong market traction with significant revenue growth and a global customer base including leading CDMOs such as Corden Pharma. Their proprietary flow-through column technology enables faster, more efficient, and scalable production of peptide and oligonucleotide therapeutics for pharmaceutical companies and CDMOs.

Modalities: PeptidesOligonucleotides
Industry: Non-Drug Biotech

Partnerships

Asahi Kasei Bioprocess America (exclusive global partnership for integration of THESYS® ACS Ergo columns into the PeptiPro® platform)

Beyond the preview

Go deeper on PeptiSystems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PeptiSystems.

Explore the full profile